{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T08:09:57Z","timestamp":1790237397719,"version":"4.1.0"},"reference-count":20,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2017,12,28]],"date-time":"2017-12-28T00:00:00Z","timestamp":1514419200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,6,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>The purpose of this study was to evaluate percutaneous transhepatic portal vein stenting (PVS) for palliation of refractory ascites and\/or variceal bleeding caused by extrahepatic portomesenteric venous stenosis in patients with pancreaticobiliary cancer.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Materials and Methods<\/jats:title>\n                  <jats:p>A single-institution, retrospective review of patients who underwent PVS between January 2007 and July 2015 was performed. A total of 38 patients were identified, of whom 28 met the inclusion criterion of PVS performed primarily for refractory ascites or variceal bleeding. In addition to technical success and overall survival, clinical success was measured by fraction of remaining life palliated. The palliative effect of PVS was also quantified by measuring changes in liver and ascites volumes after the procedure.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Technical success was 93% (26\/28). Stent deployment involved more than one portomesenteric vessel in most patients (20\/26). The cumulative probability of symptom recurrence at 6, 12, 18, and 24 months was 12%, 16%, 26%, and 40%, respectively. There was a significant difference (p\u2009&amp;lt;\u2009.001) in the probability of symptom recurrence, recurrence of abdominal ascites, and increase in liver volume between patients whose stents remained patent and those whose stents demonstrated partial or complete occlusion. The mean fraction of remaining life palliated was 87%. All but two patients were found to have improvement in clinical symptoms for the majority of their lives after the procedure. There were no major or minor complications.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>As a low-risk procedure with a high clinical success rate, PVS can play a substantial role in improving quality of life in patients with portomesenteric stenoses.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Implications for Practice<\/jats:title>\n                  <jats:p>Portomesenteric venous stenosis is a challenging complication of pancreaticobiliary malignancy. Portomesenteric stenoses can lead to esophageal, gastric, and mesenteric variceal bleeding, as well as abdominal ascites. The purpose of this study was to evaluate the safety and efficacy of portal vein stenting (PVS) in patients with cancer who have symptomatic portal hypertension caused by portomesenteric venous compression. As a low-risk procedure with a high clinical success rate, PVS can play a substantial role in improving quality of life in patients with portomesenteric stenoses.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1634\/theoncologist.2017-0337","type":"journal-article","created":{"date-parts":[[2017,12,28]],"date-time":"2017-12-28T15:56:25Z","timestamp":1514476585000},"page":"712-718","source":"Crossref","is-referenced-by-count":16,"title":["Portomesenteric Venous Stenting for Palliation of Ascites and Variceal Bleeding Caused by Prehepatic Portal Hypertension"],"prefix":"10.1093","volume":"23","author":[{"given":"Rahul A.","family":"Sheth","sequence":"first","affiliation":[{"name":"Department of Interventional Radiology, MD Anderson Cancer Center, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharjeel H.","family":"Sabir","sequence":"additional","affiliation":[{"name":"Department of Interventional Radiology, MD Anderson Cancer Center, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip","family":"Parmet","sequence":"additional","affiliation":[{"name":"Synergy Radiology Associates, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roshon","family":"Amin","sequence":"additional","affiliation":[{"name":"Department of Interventional Radiology, MD Anderson Cancer Center, Houston, Texas, USA"},{"name":"Department of Radiology, University of Texas Medical School at Houston, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua D.","family":"Kuban","sequence":"additional","affiliation":[{"name":"Department of Interventional Radiology, MD Anderson Cancer Center, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven Y.","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Interventional Radiology, MD Anderson Cancer Center, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Armeen","family":"Mahvash","sequence":"additional","affiliation":[{"name":"Department of Interventional Radiology, MD Anderson Cancer Center, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Fogelman","sequence":"additional","affiliation":[{"name":"Department of Gastrointestinal Medical Oncology, MD Anderson Cancer Center, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Milind","family":"Javle","sequence":"additional","affiliation":[{"name":"Department of Gastrointestinal Medical Oncology, MD Anderson Cancer Center, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"Wallace","sequence":"additional","affiliation":[{"name":"Department of Interventional Radiology, MD Anderson Cancer Center, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2017,12,28]]},"reference":[{"key":"2021122510550505400_onco12349-bib-0001","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1097\/COC.0b013e31828f5c82","article-title":"Direct percutaneous transhepatic portomesenteric venous stenting in management of locally advanced pancreatic cancer","volume":"38","author":"Alden","year":"2015","journal-title":"Am J Clin Oncol"},{"key":"2021122510550505400_onco12349-bib-0002","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1002\/bjs.5368","article-title":"Systematic review of outcome of synchronous portal-superior mesenteric vein resection during pancreatectomy for cancer","volume":"93","author":"Siriwardana","year":"2006","journal-title":"Br J Surg"},{"key":"2021122510550505400_onco12349-bib-0003","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1016\/j.jvir.2009.09.001","article-title":"Endovascular recanalization of symptomatic portomesenteric venous obstruction after pancreaticoduodenectomy and radiation","volume":"20","author":"Hoffer","year":"2009","journal-title":"J Vasc Interv Radiol"},{"key":"2021122510550505400_onco12349-bib-0004","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1016\/j.gassur.2006.09.001","article-title":"Durability of portal venous reconstruction following resection during pancreaticoduodenectomy","volume":"10","author":"Smoot","year":"2006","journal-title":"J Gastrointest Surg"},{"key":"2021122510550505400_onco12349-bib-0005","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1016\/j.ijrobp.2005.08.022","article-title":"Extrahepatic portal vein occlusion without recurrence after pancreaticoduodenectomy and intraoperative radiation therapy","volume":"64","author":"Mitsunaga","year":"2006","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2021122510550505400_onco12349-bib-0006","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1111\/j.1440-1746.2005.03913.x","article-title":"Late complication in patients undergoing pancreatic resection with intraoperative radiation therapy: Gastrointestinal bleeding with occlusion of the portal system","volume":"20","author":"Shimizu","year":"2005","journal-title":"J Gastroenterol Hepatol"},{"key":"2021122510550505400_onco12349-bib-0007","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1007\/s00270-015-1123-2","article-title":"Portal venous stent placement for malignant portal venous stenosis or occlusion: Who benefits?","volume":"38","author":"Hasegawa","year":"2015","journal-title":"Cardiovasc Intervent Radiol"},{"key":"2021122510550505400_onco12349-bib-0008","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1111\/ans.12046","article-title":"Clinical usefulness of portal venous stent in hepatobiliary pancreatic cancers","volume":"84","author":"Zhou","year":"2014","journal-title":"ANZ J Surg"},{"key":"2021122510550505400_onco12349-bib-0009","doi-asserted-by":"crossref","first-page":"W446","DOI":"10.2214\/AJR.10.5274","article-title":"Percutaneous transhepatic stent placement in the management of portal venous stenosis after curative surgery for pancreatic and biliary neoplasms","volume":"196","author":"Kim","year":"2011","journal-title":"AJR Am J Roentgenol"},{"key":"2021122510550505400_onco12349-bib-0010","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1007\/s00270-008-9455-9","article-title":"Palliative portal vein stent placement in malignant and symptomatic extrinsic portal vein stenosis or occlusion","volume":"32","author":"Novellas","year":"2009","journal-title":"Cardiovasc Intervent Radiol"},{"key":"2021122510550505400_onco12349-bib-0011","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/j.jvir.2009.02.010","article-title":"Portal vein venoplasty and stent placement in the nontransplant population","volume":"20","author":"Woodrum","year":"2009","journal-title":"J Vasc Interv Radiol"},{"key":"2021122510550505400_onco12349-bib-0012","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1016\/S1051-0443(07)61699-6","article-title":"Malignant portal venous obstructions treated by stent placement: Significant factors affecting patency","volume":"12","author":"Yamakado","year":"2001","journal-title":"J Vasc Interv Radiol"},{"key":"2021122510550505400_onco12349-bib-0013","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1148\/radiology.220.1.r01jl03150","article-title":"Portal venous stent placement in patients with pancreatic and biliary neoplasms invading portal veins and causing portal hypertension: Initial experience","volume":"220","author":"Yamakado","year":"2001","journal-title":"Radiology"},{"issue":"suppl 7","key":"2021122510550505400_onco12349-bib-0014","doi-asserted-by":"crossref","first-page":"S189","DOI":"10.1016\/j.jvir.2009.04.035","article-title":"Society of Interventional Radiology clinical practice guidelines","volume":"20","author":"Cardella","year":"2009","journal-title":"J Vasc Interv Radiol"},{"key":"2021122510550505400_onco12349-bib-0015","author":"R Core Team","year":"2016"},{"key":"2021122510550505400_onco12349-bib-0016","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1002\/lt.22397","article-title":"Priority of candidates with hepatocellular carcinoma awaiting liver transplantation can be reduced after successful bridge therapy","volume":"17","author":"Cucchetti","year":"2011","journal-title":"Liver Transpl"},{"key":"2021122510550505400_onco12349-bib-0017","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1038\/sj.bmt.1705727","article-title":"Competing risk analysis using R: An easy guide for clinicians","volume":"40","author":"Scrucca","year":"2007","journal-title":"Bone Marrow Transplant"},{"key":"2021122510550505400_onco12349-bib-0018","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1038\/sj.bjc.6690085","article-title":"Defining and analysing symptom palliation in cancer clinical trials: A deceptively difficult exercise","volume":"79","author":"Stephens","year":"1999","journal-title":"Br J Cancer"},{"key":"2021122510550505400_onco12349-bib-0019","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1016\/j.jpainsymman.2013.01.010","article-title":"The selection and use of outcome measures in palliative and end-of-life care research: The MORECare International Consensus Workshop","volume":"46","author":"Evans","year":"2013","journal-title":"J Pain Symptom Manage"},{"key":"2021122510550505400_onco12349-bib-0020","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1136\/thx.48.4.339","article-title":"Palliation of symptoms in non-small cell lung cancer: A study by the Yorkshire Regional Cancer Organisation Thoracic Group","volume":"48","author":"Muers","year":"1993","journal-title":"Thorax"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1634\/theoncologist.2017-0337","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1634\/theoncologist.2017-0337","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/23\/6\/712\/41916640\/oncolo_23_6_712.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/23\/6\/712\/41916640\/oncolo_23_6_712.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,25]],"date-time":"2021-12-25T10:55:54Z","timestamp":1640429754000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/23\/6\/712\/6439811"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12,28]]},"references-count":20,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2017,12,28]]},"published-print":{"date-parts":[[2018,6,1]]}},"URL":"https:\/\/doi.org\/10.1634\/theoncologist.2017-0337","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2018,6,1]]},"published":{"date-parts":[[2017,12,28]]}}}